{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:54:04Z","timestamp":1790798044377,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008131","name":"Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to report on glaucoma patients\u2019 beliefs and illness perceptions and to investigate their opinion on ocular drug delivery devices (ODD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a cross-sectional study in a large tertiary-referral outpatient glaucoma clinic, with 102 patients. Validated anonymized questionnaires were used. We investigated the awareness and acceptance regarding ODD (contact lenses (CLs), punctal plugs (PPs), subconjunctival implants, anterior chamber (AC) injections, and drug-emitting stents) and looked at factors that could influence a patient\u2019s decision for having an ODD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-three patients (61.8%) confirmed they would rather have ODD than keep their eye-drops (38.2%). The most important factors influencing their decision were effectiveness and long-lasting effect. A large proportion of patients reported a preference for CLs (48.0%), PPs (52.9%), or drug-emitting stents (44.1%). When comparing patients who preferred ODD (group-1) versus eye-drops (group-2), significantly more patients in group-1 were worried (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) or felt disrupted (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) by their use of eye-drops. A significantly greater share of patients in group-1 showed acceptance towards CLs (60.3% vs. 38.5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.032), AC injections (38.1% vs. 12.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.006), or drug-emitting stents (54% vs. 28.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.023), whilst there were no significant differences regarding the acceptance of PPs (<jats:italic>p<\/jats:italic>\u2009=\u20090.363) or subconjunctival implants (<jats:italic>p<\/jats:italic>\u2009=\u20090.058).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ODD for the treatment of glaucoma were broadly deemed acceptable by patients in this study. Effectiveness and long-lasting effect were the most important factors for a decision towards having an ODD. The majority of patients who preferred an ODD felt severely affected by their disease and were negatively influenced by their glaucoma medication intake.<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00417-023-06248-1","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T06:02:06Z","timestamp":1696053726000},"page":"545-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ocular drug delivery systems: glaucoma patient perceptions from a German university hospital eye clinic"],"prefix":"10.1007","volume":"262","author":[{"given":"Constance","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Quintin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mercieca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"6248_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archopht.119.8.1165","volume":"119","author":"DD Gaton","year":"2001","unstructured":"Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN (2001) Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 119:1165\u20131170. https:\/\/doi.org\/10.1001\/archopht.119.8.1165","journal-title":"Arch Ophthalmol"},{"key":"6248_CR2","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/s0161-6420(01)00873-9","volume":"108","author":"PR Lichter","year":"2001","unstructured":"Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP (2001) Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108:1943\u20131953. https:\/\/doi.org\/10.1016\/s0161-6420(01)00873-9","journal-title":"Ophthalmology"},{"key":"6248_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701\u2013713. https:\/\/doi.org\/10.1001\/archopht.120.6.701. (discussion 829-730)","journal-title":"Arch Ophthalmol"},{"key":"6248_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/s0140-6736(18)32213-x","volume":"393","author":"G Gazzard","year":"2019","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M (2019) Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 393:1505\u20131516. https:\/\/doi.org\/10.1016\/s0140-6736(18)32213-x","journal-title":"Lancet"},{"key":"6248_CR5","doi-asserted-by":"publisher","unstructured":"(2000) The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol 130: 429\u2013440 https:\/\/doi.org\/10.1016\/s0002-9394(00)00538-9","DOI":"10.1016\/s0002-9394(00)00538-9"},{"key":"6248_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ophtha.2009.10.038","volume":"117","author":"G Rees","year":"2010","unstructured":"Rees G, Leong O, Crowston JG, Lamoureux EL (2010) Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma. Ophthalmology 117:903\u2013908. https:\/\/doi.org\/10.1016\/j.ophtha.2009.10.038","journal-title":"Ophthalmology"},{"key":"6248_CR7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2147\/ppa.S264926","volume":"15","author":"I Tapply","year":"2021","unstructured":"Tapply I, Broadway DC (2021) Improving adherence to topical medication in patients with glaucoma. Patient Prefer Adherence 15:1477\u20131489. https:\/\/doi.org\/10.2147\/ppa.S264926","journal-title":"Patient Prefer Adherence"},{"key":"6248_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ophtha.2019.09.041","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Salman M, Lee PP, Gatwood JD (2020) Cost-utility analysis of glaucoma medication adherence. Ophthalmology 127:589\u2013598. https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.041","journal-title":"Ophthalmology"},{"key":"6248_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18240\/ijo.2021.01.21","volume":"14","author":"NP Kesav","year":"2021","unstructured":"Kesav NP, Young CEC, Ertel MK, Seibold LK, Kahook MY (2021) Sustained-release drug delivery systems for the treatment of glaucoma. Int J Ophthalmol 14:148\u2013159. https:\/\/doi.org\/10.18240\/ijo.2021.01.21","journal-title":"Int J Ophthalmol"},{"key":"6248_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1089\/jop.2020.0024","volume":"36","author":"GD Novack","year":"2020","unstructured":"Novack GD, Barnett M (2020) Ocular drug delivery systems using contact lenses. J Ocul Pharmacol Ther 36:595\u2013601. https:\/\/doi.org\/10.1089\/jop.2020.0024","journal-title":"J Ocul Pharmacol Ther"},{"key":"6248_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.biomaterials.2013.09.032","volume":"35","author":"JB Ciolino","year":"2014","unstructured":"Ciolino JB, Stefanescu CF, Ross AE, Salvador-Culla B, Cortez P, Ford EM, Wymbs KA, Sprague SL, Mascoop DR, Rudina SS, Trauger SA, Cade F, Kohane DS (2014) In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials 35:432\u2013439. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.09.032","journal-title":"Biomaterials"},{"key":"6248_CR12","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1167\/iovs.12-9536","volume":"53","author":"DF Goldberg","year":"2012","unstructured":"Goldberg DF, Williams R (2012) A phase 2 study evaluating safety and efficacy of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with ocular hypertension (OH) or open-angle glaucoma (OAG). Invest Ophthalmol Vis Sci 53:5095\u20135095","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6248_CR13","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s10792-020-01391-8","volume":"40","author":"F Rafiei","year":"2020","unstructured":"Rafiei F, Tabesh H, Farzad F (2020) Sustained subconjunctival drug delivery systems: current trends and future perspectives. Int Ophthalmol 40:2385\u20132401. https:\/\/doi.org\/10.1007\/s10792-020-01391-8","journal-title":"Int Ophthalmol"},{"key":"6248_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1089\/jop.2018.0095","volume":"35","author":"SS Lee","year":"2019","unstructured":"Lee SS, Dibas M, Almazan A, Robinson MR (2019) Dose-response of intracameral bimatoprost sustained-release implant and topical bimatoprost in lowering intraocular pressure. J Ocul Pharmacol Ther 35:138\u2013144. https:\/\/doi.org\/10.1089\/jop.2018.0095","journal-title":"J Ocul Pharmacol Ther"},{"key":"6248_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/tvst.4.3.14","volume":"4","author":"M Hovakimyan","year":"2015","unstructured":"Hovakimyan M, Siewert S, Schmidt W, Sternberg K, Reske T, Stachs O, Guthoff R, Wree A, Witt M, Schmitz KP, Allemann R (2015) Development of an experimental drug eluting suprachoroidal microstent as glaucoma drainage device. Transl Vis Sci Technol 4:14. https:\/\/doi.org\/10.1167\/tvst.4.3.14","journal-title":"Transl Vis Sci Technol"},{"key":"6248_CR16","doi-asserted-by":"publisher","first-page":"8240","DOI":"10.1167\/iovs.12-10393","volume":"53","author":"RC Foo","year":"2012","unstructured":"Foo RC, Lamoureux EL, Wong RC, Ho SW, Chiang PP, Rees G, Aung T, Wong TT (2012) Acceptance, attitudes, and beliefs of Singaporean Chinese toward an ocular implant for glaucoma drug delivery. Invest Ophthalmol Vis Sci 53:8240\u20138245. https:\/\/doi.org\/10.1167\/iovs.12-10393","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6248_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/IJG.0b013e318237c6c4","volume":"22","author":"RS Chong","year":"2013","unstructured":"Chong RS, Su DH, Tsai A, Jiang Y, Htoon HM, Lamoureux EL, Aung T, Wong TT (2013) Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma. J Glaucoma 22:190\u2013194. https:\/\/doi.org\/10.1097\/IJG.0b013e318237c6c4","journal-title":"J Glaucoma"},{"key":"6248_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s0022-3999(99)00057-4","volume":"47","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J (1999) Patients\u2019 beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555\u2013567. https:\/\/doi.org\/10.1016\/s0022-3999(99)00057-4","journal-title":"J Psychosom Res"},{"key":"6248_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jpsychores.2005.10.020","volume":"60","author":"E Broadbent","year":"2006","unstructured":"Broadbent E, Petrie KJ, Main J, Weinman J (2006) The brief illness perception questionnaire. J Psychosom Res 60:631\u2013637. https:\/\/doi.org\/10.1016\/j.jpsychores.2005.10.020","journal-title":"J Psychosom Res"},{"key":"6248_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348\u2013354. https:\/\/doi.org\/10.1111\/j.1751-7176.2008.07572.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"6248_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/ijg.0000000000000197","volume":"24","author":"HH Chan","year":"2015","unstructured":"Chan HH, Wong TT, Lamoureux E, Perera S (2015) A survey on the preference of sustained glaucoma drug delivery systems by Singaporean Chinese patients: a comparison between subconjunctival, intracameral, and punctal plug routes. J Glaucoma 24:485\u2013492. https:\/\/doi.org\/10.1097\/ijg.0000000000000197","journal-title":"J Glaucoma"},{"key":"6248_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","volume":"37","author":"M Shirley","year":"2020","unstructured":"Shirley M (2020) Bimatoprost Implant: First Approval. Drugs Aging 37:457\u2013462. https:\/\/doi.org\/10.1007\/s40266-020-00769-8","journal-title":"Drugs Aging"},{"key":"6248_CR23","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","volume":"81","author":"J Bacharach","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, Belalc\u00e1zar S, Thieme H, Goodkin ML, Chen MY, Guo Q, Liu J, Robinson MR, Bejanian M, Wirta DL (2021) Phase 3, Randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs 81:2017\u20132033. https:\/\/doi.org\/10.1007\/s40265-021-01624-9","journal-title":"Drugs"},{"key":"6248_CR24","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1002\/adhm.201600780","volume":"5","author":"YS Pek","year":"2016","unstructured":"Pek YS, Wu H, Mohamed ST, Ying JY (2016) Long-term subconjunctival delivery of brimonidine tartrate for glaucoma treatment using a microspheres\/carrier system. Adv Healthc Mater 5:2823\u20132831. https:\/\/doi.org\/10.1002\/adhm.201600780","journal-title":"Adv Healthc Mater"},{"key":"6248_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jconrel.2015.01.023","volume":"202","author":"IM Carvalho","year":"2015","unstructured":"Carvalho IM, Marques CS, Oliveira RS, Coelho PB, Costa PC, Ferreira DC (2015) Sustained drug release by contact lenses for glaucoma treatment-a review. J Control Release 202:76\u201382. https:\/\/doi.org\/10.1016\/j.jconrel.2015.01.023","journal-title":"J Control Release"},{"key":"6248_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jconrel.2016.02.012","volume":"226","author":"FA Maulvi","year":"2016","unstructured":"Maulvi FA, Lakdawala DH, Shaikh AA, Desai AR, Choksi HH, Vaidya RJ, Ranch KM, Koli AR, Vyas BA, Shah DO (2016) In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery. J Control Release 226:47\u201356. https:\/\/doi.org\/10.1016\/j.jconrel.2016.02.012","journal-title":"J Control Release"},{"key":"6248_CR27","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00417-017-3755-1","volume":"255","author":"J Xie","year":"2017","unstructured":"Xie J, Wang C, Ning Q, Gao Q, Gao C, Gou Z, Ye J (2017) A new strategy to sustained release of ocular drugs by one-step drug-loaded microcapsule manufacturing in hydrogel punctal plugs. Graefes Arch Clin Exp Ophthalmol 255:2173\u20132184. https:\/\/doi.org\/10.1007\/s00417-017-3755-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6248_CR28","doi-asserted-by":"publisher","unstructured":"Xu X, Awwad S, Diaz-Gomez L, Alvarez-Lorenzo C, Brocchini S, Gaisford S, Goyanes A, Basit AW (2021) 3D printed punctal plugs for controlled ocular drug delivery. Pharmaceutics\u00a013(9):1421.\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics13091421","DOI":"10.3390\/pharmaceutics13091421"},{"key":"6248_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/08820538.2016.1228406","volume":"32","author":"A Joseph","year":"2017","unstructured":"Joseph A, Pasquale LR (2017) Attributes associated with adherence to glaucoma medical therapy and its effects on glaucoma outcomes: an evidence-based review and potential strategies to improve adherence. Semin Ophthalmol 32:86\u201390. https:\/\/doi.org\/10.1080\/08820538.2016.1228406","journal-title":"Semin Ophthalmol"},{"key":"6248_CR30","doi-asserted-by":"publisher","first-page":"109006","DOI":"10.1016\/j.exer.2022.109006","volume":"218","author":"Y Yang","year":"2022","unstructured":"Yang Y, Lockwood A (2022) Topical ocular drug delivery systems: innovations for an unmet need. Exp Eye Res 218:109006. https:\/\/doi.org\/10.1016\/j.exer.2022.109006","journal-title":"Exp Eye Res"},{"key":"6248_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","volume":"130","author":"G Gazzard","year":"2023","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, Adeleke M, Vickerstaff V, Ambler G, Hunter R, Bunce C, Nathwani N, Barton K (2023) Laser in glaucoma and ocular hypertension (LiGHT) trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology 130:139\u2013151. https:\/\/doi.org\/10.1016\/j.ophtha.2022.09.009","journal-title":"Ophthalmology"},{"key":"6248_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ogla.2020.08.010","volume":"4","author":"D Gupta","year":"2021","unstructured":"Gupta D, Ehrlich JR, Newman-Casey PA, Stagg B (2021) Cost-related medication nonadherence in a nationally representative US population with self-reported glaucoma. Ophthalmol Glaucoma 4:126\u2013130. https:\/\/doi.org\/10.1016\/j.ogla.2020.08.010","journal-title":"Ophthalmol Glaucoma"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06248-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06248-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06248-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T09:05:47Z","timestamp":1707123947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06248-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6248"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06248-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained by the local ethics committee of the University Hospital Bonn (reference: 185\/22). The study protocol conformed to the ethical guidelines of the 2000 Declaration of Helsinki as reflected in a priori approval by the institution\u2019s Human Research Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients participated anonymously after giving fully informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"CW, PQ, and FGH certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest, and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. KM and AF have received honoraria or research grants from the following: Allergan\/Abbvie (C,H,R) and Glaukos (C,H,R), but none of this is related to the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}